A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
Status:
Recruiting
Trial end date:
2025-12-02
Target enrollment:
Participant gender:
Summary
10 participants are expected to be enrolled for this open，Single-armed clinical trial to
evaluate the safety, tolerability, and efficacy of the recombinant herpes simplex virus I,
R130 in patients with relapsed/refractory ovarian cancer.